Carla E. M. Hollak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carla E. M. Hollak has a total of 328 co-authors. Here are the top co-authors by number of shared publications:
- Johannes M. F. G. Aerts
Department of Medical Biochemistry and Department of Bio‐organic Synthesis Leiden Institute of Chemistry (LIC) Leiden University Leiden the Netherlands
23 shared publications - Marieke Biegstraaten
Department of Internal Medicine, Division Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands
9 shared publications - Gabor E. Linthorst
Amsterdam UMC, afd. Inwendige geneeskunde, Endocrinologie en Metabolisme, locatie UvA-AMC
8 shared publications - Derralynn A. Hughes
Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust, London, UK
6 shared publications - Frits A. Wijburg
Academic Medical Center, Amsterdam, The Netherlands
6 shared publications - Mirjam Langeveld
Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
6 shared publications
Latest Publications
- 1 November 2018
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 125 (3) , 205-216
Development and clinical consequences of white matter lesions in Fabry disease: a systematic review
- 1 November 2018
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 125 (3) , 205-216
Development and clinical consequences of white matter lesions in Fabry disease: a systematic review
- Open Access
- 1 September 2018
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 41 (5) , 899-900
Editorial
- 1 September 2018
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 41 (5) , 899-900
Open AccessEditorial
- Open Access
- 29 August 2018
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 13 (1) , 1-6
Can untreated PKU patients escape from intellectual disability? A systematic review
Phenylketonuria (PKU) is often considered as the classical example of a genetic disorder in which severe symptoms can nowadays successfully be prevented by early diagnosis and treatment. In contrast, untreated or late-treated PKU is known to result in severe intellectual disability, seizures, and behavioral disturbances. Rarely, however, untreated or late-diagnosed PKU patients with high plasma phenylalanine concentrations have been reported to escape from intellectual disability. The present study aimed to review published cases of such PKU patients. To this purpose, we conducted a literature search in PubMed and EMBASE up to 8th of September 2017 to identify cases with 1) PKU diagnosis and start of treatment after 7 years of age; 2) untreated plasma phenylalanine concentrations ≥1200 μmol/l; and 3) IQ ≥80. Literature search, checking reference lists, selection of articles, and extraction of data were performed by two independent researchers. In total, we identified 59 published cases of patients with late-diagnosed PKU and unexpected favorable outcome who met the inclusion criteria. Although all investigated patients had intellectual functioning within the normal range, at least 19 showed other neurological, psychological, and/or behavioral symptoms. Based on the present findings, the classical symptomatology of untreated or late-treated PKU may need to be rewritten, not only in the sense that intellectual dysfunction is not obligatory, but also in the sense that intellectual functioning does not (re)present the full picture of brain damage due to high plasma phenylalanine concentrations. Further identification of such patients and additional analyses are necessary to better understand these differences between PKU patients.
- 29 August 2018
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 13 (1) , 1-6
Open AccessCan untreated PKU patients escape from intellectual disability? A systematic review
Phenylketonuria (PKU) is often considered as the classical example of a genetic disorder in which severe symptoms can nowadays successfully be prevented by early diagnosis and treatment. In contrast, untreated or late-treated PKU is known to result in severe intellectual disability, seizures, and behavioral disturbances. Rarely, however, untreated or late-diagnosed PKU patients with high plasma phenylalanine concentrations have been reported to escape from intellectual disability. The present study aimed to review published cases of such PKU patients. To this purpose, we conducted a literature search in PubMed and EMBASE up to 8th of September 2017 to identify cases with 1) PKU diagnosis and start of treatment after 7 years of age; 2) untreated plasma phenylalanine concentrations ≥1200 μmol/l; and 3) IQ ≥80. Literature search, checking reference lists, selection of articles, and extraction of data were performed by two independent researchers. In total, we identified 59 published cases of patients with late-diagnosed PKU and unexpected favorable outcome who met the inclusion criteria. Although all investigated patients had intellectual functioning within the normal range, at least 19 showed other neurological, psychological, and/or behavioral symptoms. Based on the present findings, the classical symptomatology of untreated or late-treated PKU may need to be rewritten, not only in the sense that intellectual dysfunction is not obligatory, but also in the sense that intellectual functioning does not (re)present the full picture of brain damage due to high plasma phenylalanine concentrations. Further identification of such patients and additional analyses are necessary to better understand these differences between PKU patients.
- Open Access
- 1 June 2018
- Published by Elsevier in Drug Discovery Today
- Vol. 23 (6) , 1251-1257
Adaptive pathway development for Fabry disease: a clinical approach
- 1 June 2018
- Published by Elsevier in Drug Discovery Today
- Vol. 23 (6) , 1251-1257
Open AccessAdaptive pathway development for Fabry disease: a clinical approach
- Open Access
- 27 April 2018
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 41 (5) , 839-848
Mucolipidosis type III, a series of adult patients
Background: Mucolipidosis type III α/β or γ (MLIII) are rare autosomal recessive diseases, in which reduced activity of the enzyme UDP‐N‐acetyl glucosamine‐1‐phosphotransferase (GlcNAc‐PTase) leads to intra‐lysosomal accumulation of different substrates. Publications on the natural history of MLIII, especially the milder forms, are scarce. This study provides a detailed description of the disease characteristics and its natural course in adult patients with MLIII.Methods: In this retrospective chart study, the clinical, biochemical and molecular findings in adult patients with a confirmed diagnosis of MLIII from three treatment centres were collected.Results: Thirteen patients with MLIII were included in this study. Four patients (31%) were initially misdiagnosed with a type of mucopolysaccharidosis (MPS). Four patients (31%) had mild cognitive impairment. Six patients (46%) needed help with activities of daily living (ADL) or were wheelchair‐dependent. All patients had dysostosis multiplex and progressive secondary osteoarthritis, characterised by cartilage destruction and bone lesions in multiple joints. All patients underwent multiple orthopaedic surgical interventions as early as the second or third decades of life, of which total hip replacement (THR) was the most common procedure (61% of patients). Carpal tunnel syndrome (CTS) was found in 12 patients (92%) and in eight patients (61%), CTS release was performed.Conclusions: Severe skeletal abnormalities, resulting from abnormal bone development and severe progressive osteoarthritis, are the hallmark of MLIII, necessitating surgical orthopaedic interventions early in life. Future therapies for this disease should focus on improving cartilage and bone quality, preventing skeletal complications and improving mobility.
- 27 April 2018
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 41 (5) , 839-848
Open AccessMucolipidosis type III, a series of adult patients
Background: Mucolipidosis type III α/β or γ (MLIII) are rare autosomal recessive diseases, in which reduced activity of the enzyme UDP‐N‐acetyl glucosamine‐1‐phosphotransferase (GlcNAc‐PTase) leads to intra‐lysosomal accumulation of different substrates. Publications on the natural history of MLIII, especially the milder forms, are scarce. This study provides a detailed description of the disease characteristics and its natural course in adult patients with MLIII.Methods: In this retrospective chart study, the clinical, biochemical and molecular findings in adult patients with a confirmed diagnosis of MLIII from three treatment centres were collected.Results: Thirteen patients with MLIII were included in this study. Four patients (31%) were initially misdiagnosed with a type of mucopolysaccharidosis (MPS). Four patients (31%) had mild cognitive impairment. Six patients (46%) needed help with activities of daily living (ADL) or were wheelchair‐dependent. All patients had dysostosis multiplex and progressive secondary osteoarthritis, characterised by cartilage destruction and bone lesions in multiple joints. All patients underwent multiple orthopaedic surgical interventions as early as the second or third decades of life, of which total hip replacement (THR) was the most common procedure (61% of patients). Carpal tunnel syndrome (CTS) was found in 12 patients (92%) and in eight patients (61%), CTS release was performed.Conclusions: Severe skeletal abnormalities, resulting from abnormal bone development and severe progressive osteoarthritis, are the hallmark of MLIII, necessitating surgical orthopaedic interventions early in life. Future therapies for this disease should focus on improving cartilage and bone quality, preventing skeletal complications and improving mobility.
- Open Access
- 8 February 2018
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 41 (5) , 819-827
Hepatocellular carcinoma in Gaucher disease: an international case series
Gaucher disease (GD) is associated with an increased risk for malignancies. Next to hematological malignancies, the development of solid tumors in several organs has been described. The liver is one of the major storage sites involved in GD pathogenesis, and is also affected by liver‐specific complications. In this case series, we describe 16 GD type 1 (GD1) patients from eight different referral centers around the world who developed hepatocellular carcinoma (HCC). Potential factors contributing to the increased HCC risk in GD patients are studied. Eleven patients had undergone a splenectomy in the past. Liver cirrhosis, one of the main risk factors for the development of HCC, was present in nine out of 14 patients for whom data was available. Three out of seven examined patients showed a transferrin saturation > 45%. In these three patients the presence of iron overload after histopathological examination of the liver was shown. Chronic hepatitis C infection was present in three of 14 examined cases. We summarized all findings and made a comparison to the literature. We recommend that GD patients, especially those with prior splenectomy or iron overload, be evaluated for signs of liver fibrosis and if found to be monitored for HCC development.
- 8 February 2018
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 41 (5) , 819-827
Open AccessHepatocellular carcinoma in Gaucher disease: an international case series
Gaucher disease (GD) is associated with an increased risk for malignancies. Next to hematological malignancies, the development of solid tumors in several organs has been described. The liver is one of the major storage sites involved in GD pathogenesis, and is also affected by liver‐specific complications. In this case series, we describe 16 GD type 1 (GD1) patients from eight different referral centers around the world who developed hepatocellular carcinoma (HCC). Potential factors contributing to the increased HCC risk in GD patients are studied. Eleven patients had undergone a splenectomy in the past. Liver cirrhosis, one of the main risk factors for the development of HCC, was present in nine out of 14 patients for whom data was available. Three out of seven examined patients showed a transferrin saturation > 45%. In these three patients the presence of iron overload after histopathological examination of the liver was shown. Chronic hepatitis C infection was present in three of 14 examined cases. We summarized all findings and made a comparison to the literature. We recommend that GD patients, especially those with prior splenectomy or iron overload, be evaluated for signs of liver fibrosis and if found to be monitored for HCC development.
- Open Access
- 1 February 2018
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 68, 203-208
Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease
- 1 February 2018
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 68, 203-208
Open AccessManagement goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease
- 1 February 2018
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 123 (2) , 76-84
Rapid screening for lipid storage disorders using biochemical markers. Expert center data and review of the literature
- 1 February 2018
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 123 (2) , 76-84
Rapid screening for lipid storage disorders using biochemical markers. Expert center data and review of the literature
- Open Access
- 16 October 2017
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 41 (1) , 141-149
Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study
Quality of life (QoL) is decreased in patients with Fabry disease (FD). To improve QoL, it is important to understand the influence of FD related characteristics, symptoms, and complications. In this retrospective cohort study we explored the effect of pain (measured by the Brief Pain Inventory), phenotype, treatment, and FD‐related complications on QoL. QoL data of Fabry patients as assessed by the EuroQol five dimension questionnaire (EQ‐5D) from two international centers of excellence were collected. The aim of this study was to evaluate the effect of sex, phenotype, age, different states of disease severity, pain, and ERT on EQ‐5D utilities. For 286 adult FD patients (mean age 42.5 years, 40% men, 60% classical phenotype) 2240 EQ‐5Ds were available. QoL is decreased in men as well as women with FD, especially in older men with a classical phenotype. At age 50, utility was lower in men with classical FD compared to those with non‐classical disease (β = −0.12, 95% CI: ‐0.23 – 0.01, p = 0.037) with further difference in the years thereafter. Cardiovascular complications, stroke or transient ischemic attacks, multiple FD‐related complications and pain were also associated with decreased utilities. Overall, no change in utility was seen in patients on ERT over a mean follow‐up of 6.1 years. FD leads to a decreased QoL compared to the general population. Disease complications and pain both negatively influence QoL. Adequate assessment and treatment of pain as well as improved strategies to prevent disease complications are needed to improve QoL in the FD population.
- 16 October 2017
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 41 (1) , 141-149
Open AccessPhenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study
Quality of life (QoL) is decreased in patients with Fabry disease (FD). To improve QoL, it is important to understand the influence of FD related characteristics, symptoms, and complications. In this retrospective cohort study we explored the effect of pain (measured by the Brief Pain Inventory), phenotype, treatment, and FD‐related complications on QoL. QoL data of Fabry patients as assessed by the EuroQol five dimension questionnaire (EQ‐5D) from two international centers of excellence were collected. The aim of this study was to evaluate the effect of sex, phenotype, age, different states of disease severity, pain, and ERT on EQ‐5D utilities. For 286 adult FD patients (mean age 42.5 years, 40% men, 60% classical phenotype) 2240 EQ‐5Ds were available. QoL is decreased in men as well as women with FD, especially in older men with a classical phenotype. At age 50, utility was lower in men with classical FD compared to those with non‐classical disease (β = −0.12, 95% CI: ‐0.23 – 0.01, p = 0.037) with further difference in the years thereafter. Cardiovascular complications, stroke or transient ischemic attacks, multiple FD‐related complications and pain were also associated with decreased utilities. Overall, no change in utility was seen in patients on ERT over a mean follow‐up of 6.1 years. FD leads to a decreased QoL compared to the general population. Disease complications and pain both negatively influence QoL. Adequate assessment and treatment of pain as well as improved strategies to prevent disease complications are needed to improve QoL in the FD population.
- 14 September 2017
- Published by Wiley in British Journal of Haematology
- Vol. 179 (4) , 635-647
Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment
Summary: Gaucher disease (GD) is a lysosomal storage disorder characterized by the storage of glycosphingolipids in macrophages. Despite effective therapy, residual disease is present in varying degrees and may be associated with late complications, such as persistent bone or liver disease and increased cancer risk. Gaucher macrophages are capable of storing iron and locations of residual disease may thus be detectable with iron imaging. Forty type 1 GD (GD1) patients and 40 matched healthy controls were examined using a whole‐body magnetic resonance imaging protocol consisting of standard sequences, allowing analysis of iron content per organ, expressed as R2* (Hz). Median R2* values were significantly elevated in GD1 patients as compared to healthy controls in liver [41 Hz (range 29–165) vs. 38 Hz (range 28–53), P < 0·01], femoral bone marrow [54 Hz (range 37–129) vs. 49 Hz (range 39–69), P = 0·036] and vertebral bone marrow (118 Hz (range 82–210) vs. 105 Hz (range 76–149), P < 0·01). In the spleen, primarily focal Gaucher lesions known as Gaucheroma were found to have increased R2* values. R2* values of liver, spleen and vertebral bone marrow strongly correlated with serum ferritin levels. GD1 patients with persistent hyperferritinaemia demonstrate increased iron levels in liver and bone marrow, which may carry a risk for liver fibrosis and cancer.
- 14 September 2017
- Published by Wiley in British Journal of Haematology
- Vol. 179 (4) , 635-647
Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment
Summary: Gaucher disease (GD) is a lysosomal storage disorder characterized by the storage of glycosphingolipids in macrophages. Despite effective therapy, residual disease is present in varying degrees and may be associated with late complications, such as persistent bone or liver disease and increased cancer risk. Gaucher macrophages are capable of storing iron and locations of residual disease may thus be detectable with iron imaging. Forty type 1 GD (GD1) patients and 40 matched healthy controls were examined using a whole‐body magnetic resonance imaging protocol consisting of standard sequences, allowing analysis of iron content per organ, expressed as R2* (Hz). Median R2* values were significantly elevated in GD1 patients as compared to healthy controls in liver [41 Hz (range 29–165) vs. 38 Hz (range 28–53), P < 0·01], femoral bone marrow [54 Hz (range 37–129) vs. 49 Hz (range 39–69), P = 0·036] and vertebral bone marrow (118 Hz (range 82–210) vs. 105 Hz (range 76–149), P < 0·01). In the spleen, primarily focal Gaucher lesions known as Gaucheroma were found to have increased R2* values. R2* values of liver, spleen and vertebral bone marrow strongly correlated with serum ferritin levels. GD1 patients with persistent hyperferritinaemia demonstrate increased iron levels in liver and bone marrow, which may carry a risk for liver fibrosis and cancer.